GGrantIndex
← Search

Developmental Funds

$988,726P30FY2021CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

DEVELOPMENTAL FUNDS PROJECT SUMMARY/ABSTRACT The use of developmental funds is crucial for the Case Comprehensive Cancer Center (Case CCC), providing discretionary support for strategic priorities and augmenting its Research Programs and new initiatives. In the current grant cycle, funds have supported recruitments, emerging technology Shared Resources (SRs), and Research Program-aligned and prioritized pilot projects. In addition, the institutional support for additional resources that expand the research scope and accomplishments has increased substantially over the grant period. The Specific Aims of the Developmental Funds are to: 1. Support high impact recruitments across the Center who will establish Research Programs that aim to provide basic, translational and/or clinical impact to cancer research in terms of the etiology of cancer, prevention, detection and treatment. 2. Support innovative infrastructure emerging as new Shared Resources that enable investigators to conduct high quality transdisciplinary research. 3. Support new research initiatives aligned with the Center?s Strategic Plan and coordinated through its Research Programs that advance new discoveries towards high-impact, and that emphasize collaborative efforts across programs and disciplines. 4. Support early-phase clinical investigation through support for clinical investigators and support for clinical trials staff that manage these early-phase studies. 5. Continue to leverage CCSG developmental fund investments with institutional support to expand the program effort and speed its overall impact across the Center. Use of developmental funds will be aligned with the Case CCC?s Strategic Plan and coordinated through the Executive Committee. Funds will be used to support the following activities: i) Recruitments: the Center will identify two recruitments per year with augmented packages; ii) New Shared Resource Initiatives: the Center will use funds to help develop new Shared Resources; iii) Pilot Grants: grants will be awarded to each Research Program that are collaborative and interdisciplinary in order to encourage large multi-investigator initiatives; iv) Early Phase Therapeutics: up to three clinical investigators will be supported at 20% effort each and clinical trials support staff will be supported to facilitate investigator-initiated clinical trials.

View original record on NIH RePORTER →